{"transactions":[{"id":920240,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T21:34:05.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":90000,"derivative":{"exercise_price":16.76,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001628280-26-005474","document":"wk-form4_1770240841.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000162828026005474/wk-form4_1770240841.xml","form_type":"4"}},{"id":1029941,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-01T20:57:33.000Z","date":"2025-09-29","kind":"exercise","planned":true,"acquired":false,"shares":33807,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares underlying this option vested on August 13, 2025, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":101423,"derivative":{"exercise_price":9.2435,"expiration_date":"2034-08-13","underlying":"Common Stock","underlying_shares":33807},"source":{"system":"sec-edgar","filing":"0001883986-25-000009","document":"wk-form4_1759352250.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000188398625000009/wk-form4_1759352250.xml","form_type":"4"}},{"id":1029940,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-01T20:57:33.000Z","date":"2025-09-29","kind":"sale","planned":true,"acquired":false,"shares":33807,"price":14.75,"value":498653.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001883986-25-000009","document":"wk-form4_1759352250.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000188398625000009/wk-form4_1759352250.xml","form_type":"4"}},{"id":1029939,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-01T20:57:33.000Z","date":"2025-09-29","kind":"exercise","planned":true,"acquired":true,"shares":33807,"price":9.2435,"value":312495.0045,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024."}],"balance_after":33807,"source":{"system":"sec-edgar","filing":"0001883986-25-000009","document":"wk-form4_1759352250.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000188398625000009/wk-form4_1759352250.xml","form_type":"4"}},{"id":1038626,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-17T21:01:09.000Z","date":"2025-09-15","kind":"exercise","planned":true,"acquired":false,"shares":9744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying this option vested on November 27, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":87699,"derivative":{"exercise_price":5.45,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":9744},"source":{"system":"sec-edgar","filing":"0001883986-25-000006","document":"wk-form4_1758142866.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000188398625000006/wk-form4_1758142866.xml","form_type":"4"}},{"id":1038625,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-17T21:01:09.000Z","date":"2025-09-15","kind":"exercise","planned":true,"acquired":false,"shares":6085,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":54769,"derivative":{"exercise_price":5.45,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":6085},"source":{"system":"sec-edgar","filing":"0001883986-25-000006","document":"wk-form4_1758142866.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000188398625000006/wk-form4_1758142866.xml","form_type":"4"}},{"id":1038624,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-09-17T21:01:09.000Z","date":"2025-09-15","kind":"sale","planned":true,"acquired":false,"shares":15829,"price":11.49,"value":181875.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.34 to $11.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001883986-25-000006","document":"wk-form4_1758142866.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000188398625000006/wk-form4_1758142866.xml","form_type":"4"}},{"id":1038623,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-09-17T21:01:09.000Z","date":"2025-09-15","kind":"exercise","planned":true,"acquired":true,"shares":15829,"price":5.45,"value":86268.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024."}],"balance_after":15829,"source":{"system":"sec-edgar","filing":"0001883986-25-000006","document":"wk-form4_1758142866.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000188398625000006/wk-form4_1758142866.xml","form_type":"4"}},{"id":1106939,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T21:12:19.000Z","date":"2025-06-16","kind":"exercise","planned":true,"acquired":false,"shares":9744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying this option vested on November 27, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":97443,"derivative":{"exercise_price":5.45,"expiration_date":"2033-12-10","underlying":"Common Stock","underlying_shares":9744},"source":{"system":"sec-edgar","filing":"0002023658-25-000085","document":"wk-form4_1750281133.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000202365825000085/wk-form4_1750281133.xml","form_type":"4"}},{"id":1106938,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T21:12:19.000Z","date":"2025-06-16","kind":"exercise","planned":true,"acquired":false,"shares":6085,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":60854,"derivative":{"exercise_price":5.45,"expiration_date":"2033-12-10","underlying":"Common Stock","underlying_shares":6085},"source":{"system":"sec-edgar","filing":"0002023658-25-000085","document":"wk-form4_1750281133.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000202365825000085/wk-form4_1750281133.xml","form_type":"4"}},{"id":1106937,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-06-18T21:12:19.000Z","date":"2025-06-16","kind":"sale","planned":true,"acquired":false,"shares":15829,"price":10.43,"value":165096.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.03 to $10.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0002023658-25-000085","document":"wk-form4_1750281133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000202365825000085/wk-form4_1750281133.xml","form_type":"4"}},{"id":1106936,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-06-18T21:12:19.000Z","date":"2025-06-16","kind":"exercise","planned":true,"acquired":true,"shares":15829,"price":5.45,"value":86268.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024."}],"balance_after":15829,"source":{"system":"sec-edgar","filing":"0002023658-25-000085","document":"wk-form4_1750281133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000202365825000085/wk-form4_1750281133.xml","form_type":"4"}},{"id":1202056,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-18T22:35:25.000Z","date":"2025-03-14","kind":"exercise","planned":true,"acquired":false,"shares":30246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":67119,"derivative":{"exercise_price":5.45,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":30246},"source":{"system":"sec-edgar","filing":"0000950170-25-041546","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000095017025041546/ownership.xml","form_type":"4"}},{"id":1202055,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-18T22:35:25.000Z","date":"2025-03-14","kind":"exercise","planned":true,"acquired":false,"shares":48720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying this option vested on November 27, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":107187,"derivative":{"exercise_price":5.45,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":48720},"source":{"system":"sec-edgar","filing":"0000950170-25-041546","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000095017025041546/ownership.xml","form_type":"4"}},{"id":1202054,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-03-18T22:35:25.000Z","date":"2025-03-14","kind":"sale","planned":true,"acquired":false,"shares":30620,"price":13.2434,"value":405512.908,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.05 to $13.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-041546","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000095017025041546/ownership.xml","form_type":"4"}},{"id":1202053,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-03-18T22:35:25.000Z","date":"2025-03-14","kind":"sale","planned":true,"acquired":false,"shares":48526,"price":12.688,"value":615697.888,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.05 to $13.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":30620,"source":{"system":"sec-edgar","filing":"0000950170-25-041546","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000095017025041546/ownership.xml","form_type":"4"}},{"id":1202052,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-03-18T22:35:25.000Z","date":"2025-03-14","kind":"exercise","planned":true,"acquired":true,"shares":79146,"price":5.45,"value":431345.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024."}],"balance_after":79145,"source":{"system":"sec-edgar","filing":"0000950170-25-041546","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000095017025041546/ownership.xml","form_type":"4"}},{"id":1850579,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T21:23:01.000Z","date":"2023-06-16","kind":"exercise","planned":false,"acquired":false,"shares":28,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":37453,"derivative":{"exercise_price":23.03,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":28},"source":{"system":"sec-edgar","filing":"0000899243-23-015998","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323015998/doc4.xml","form_type":"4"}},{"id":1850578,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T21:23:01.000Z","date":"2023-06-15","kind":"exercise","planned":false,"acquired":false,"shares":2269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":37481,"derivative":{"exercise_price":23.03,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":2269},"source":{"system":"sec-edgar","filing":"0000899243-23-015998","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323015998/doc4.xml","form_type":"4"}},{"id":1850577,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-20T21:23:01.000Z","date":"2023-06-16","kind":"sale","planned":false,"acquired":false,"shares":27,"price":28.35,"value":765.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to the Plan."}],"balance_after":29971,"source":{"system":"sec-edgar","filing":"0000899243-23-015998","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323015998/doc4.xml","form_type":"4"}},{"id":1850576,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-20T21:23:01.000Z","date":"2023-06-16","kind":"exercise","planned":false,"acquired":true,"shares":27,"price":23.03,"value":621.81,"ownership":{"direct":true},"balance_after":29998,"source":{"system":"sec-edgar","filing":"0000899243-23-015998","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323015998/doc4.xml","form_type":"4"}},{"id":1850575,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-20T21:23:01.000Z","date":"2023-06-15","kind":"sale","planned":false,"acquired":false,"shares":2269,"price":28.02,"value":63577.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the \"Plan\") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the \"Plan\") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":29971,"source":{"system":"sec-edgar","filing":"0000899243-23-015998","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323015998/doc4.xml","form_type":"4"}},{"id":1850574,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-20T21:23:01.000Z","date":"2023-06-15","kind":"exercise","planned":false,"acquired":true,"shares":2269,"price":23.03,"value":52255.07,"ownership":{"direct":true},"balance_after":32240,"source":{"system":"sec-edgar","filing":"0000899243-23-015998","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323015998/doc4.xml","form_type":"4"}},{"id":1865674,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-06T23:41:29.000Z","date":"2023-06-06","kind":"exercise","planned":true,"acquired":false,"shares":5126,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":84375,"derivative":{"exercise_price":18.51,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":5126},"source":{"system":"sec-edgar","filing":"0000899243-23-014615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323014615/doc4.xml","form_type":"4"}},{"id":1865673,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-06T23:41:29.000Z","date":"2023-06-05","kind":"exercise","planned":true,"acquired":false,"shares":499,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":89501,"derivative":{"exercise_price":18.51,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":499},"source":{"system":"sec-edgar","filing":"0000899243-23-014615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323014615/doc4.xml","form_type":"4"}},{"id":1865672,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-06T23:41:29.000Z","date":"2023-06-02","kind":"exercise","planned":true,"acquired":false,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested 25% on September 22, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":18128,"derivative":{"exercise_price":14,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0000899243-23-014615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323014615/doc4.xml","form_type":"4"}},{"id":1865671,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-06T23:41:29.000Z","date":"2023-06-06","kind":"sale","planned":true,"acquired":false,"shares":5126,"price":25.02,"value":128252.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was executed pursuant to the Plan in multiple trades at prices ranging from $25.00 to $25.155. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed pursuant to the Plan in multiple trades at prices ranging from $25.00 to $25.155. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":29971,"source":{"system":"sec-edgar","filing":"0000899243-23-014615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323014615/doc4.xml","form_type":"4"}},{"id":1865670,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-06T23:41:29.000Z","date":"2023-06-06","kind":"exercise","planned":true,"acquired":true,"shares":5126,"price":18.51,"value":94882.26,"ownership":{"direct":true},"balance_after":35097,"source":{"system":"sec-edgar","filing":"0000899243-23-014615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323014615/doc4.xml","form_type":"4"}},{"id":1865669,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-06T23:41:29.000Z","date":"2023-06-05","kind":"sale","planned":true,"acquired":false,"shares":499,"price":25.03,"value":12489.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to the Plan in multiple trades at prices ranging from $25.02 to $25.035. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed pursuant to the Plan in multiple trades at prices ranging from $25.02 to $25.035. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":29971,"source":{"system":"sec-edgar","filing":"0000899243-23-014615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323014615/doc4.xml","form_type":"4"}},{"id":1865668,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-06T23:41:29.000Z","date":"2023-06-05","kind":"exercise","planned":true,"acquired":true,"shares":499,"price":18.51,"value":9236.49,"ownership":{"direct":true},"balance_after":30470,"source":{"system":"sec-edgar","filing":"0000899243-23-014615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323014615/doc4.xml","form_type":"4"}},{"id":1865667,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-06T23:41:29.000Z","date":"2023-06-02","kind":"sale","planned":true,"acquired":false,"shares":1875,"price":24.21,"value":45393.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the \"Plan\") in multiple trades at prices ranging from $23.89 to $24.61. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the \"Plan\") in multiple trades at prices ranging from $23.89 to $24.61. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":29971,"source":{"system":"sec-edgar","filing":"0000899243-23-014615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323014615/doc4.xml","form_type":"4"}},{"id":1865666,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-06-06T23:41:29.000Z","date":"2023-06-02","kind":"exercise","planned":true,"acquired":true,"shares":1875,"price":14,"value":26250.0,"ownership":{"direct":true},"balance_after":31846,"source":{"system":"sec-edgar","filing":"0000899243-23-014615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323014615/doc4.xml","form_type":"4"}},{"id":1959808,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2023-03-10T21:05:12.000Z","date":"2023-03-09","kind":"sale","acquired":false,"shares":29971,"price":29.07,"value":871256.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.23 to $29.81. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.23 to $29.81. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-007996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323007996/doc4.xml","form_type":"4"}},{"id":2023610,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-10T21:47:55.000Z","date":"2023-02-08","kind":"grant","acquired":true,"shares":108000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in equal monthly installments through February 8, 2027, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":108000,"derivative":{"exercise_price":34.2,"expiration_date":"2033-02-08","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0000899243-23-004588","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323004588/doc4.xml","form_type":"4"}},{"id":2046820,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-25T23:04:31.000Z","date":"2023-01-23","kind":"exercise","acquired":false,"shares":1872,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested 25% on September 22, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":20003,"derivative":{"exercise_price":14,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":1872},"source":{"system":"sec-edgar","filing":"0000899243-23-002674","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323002674/doc4.xml","form_type":"4"}},{"id":2046819,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-25T23:04:31.000Z","date":"2023-01-23","kind":"exercise","acquired":false,"shares":4971,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":39750,"derivative":{"exercise_price":23.03,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":4971},"source":{"system":"sec-edgar","filing":"0000899243-23-002674","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323002674/doc4.xml","form_type":"4"}},{"id":2046818,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2023-01-25T23:04:31.000Z","date":"2023-01-23","kind":"sale","acquired":false,"shares":6843,"price":35.66,"value":244021.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $35.22 to $36.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $35.22 to $36.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-002674","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323002674/doc4.xml","form_type":"4"}},{"id":2046817,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2023-01-25T23:04:31.000Z","date":"2023-01-23","kind":"exercise","acquired":true,"shares":1872,"price":14,"value":26208.0,"ownership":{"direct":true},"balance_after":6843,"source":{"system":"sec-edgar","filing":"0000899243-23-002674","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323002674/doc4.xml","form_type":"4"}},{"id":2046816,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2023-01-25T23:04:31.000Z","date":"2023-01-23","kind":"exercise","acquired":true,"shares":4971,"price":23.03,"value":114482.13,"ownership":{"direct":true},"balance_after":4971,"source":{"system":"sec-edgar","filing":"0000899243-23-002674","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924323002674/doc4.xml","form_type":"4"}},{"id":2078148,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-22T21:42:42.000Z","date":"2022-12-21","kind":"exercise","acquired":false,"shares":16326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":44721,"derivative":{"exercise_price":23.03,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":16326},"source":{"system":"sec-edgar","filing":"0000899243-22-039217","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322039217/doc4.xml","form_type":"4"}},{"id":2078147,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-22T21:42:42.000Z","date":"2022-12-20","kind":"exercise","acquired":false,"shares":600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":61047,"derivative":{"exercise_price":23.03,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":600},"source":{"system":"sec-edgar","filing":"0000899243-22-039217","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322039217/doc4.xml","form_type":"4"}},{"id":2078146,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2022-12-22T21:42:42.000Z","date":"2022-12-21","kind":"sale","acquired":false,"shares":16326,"price":29.19,"value":476555.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.01 to $29.5665. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.01 to $29.5665. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-039217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322039217/doc4.xml","form_type":"4"}},{"id":2078145,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2022-12-22T21:42:42.000Z","date":"2022-12-21","kind":"exercise","acquired":true,"shares":16326,"price":23.03,"value":375987.78,"ownership":{"direct":true},"balance_after":16326,"source":{"system":"sec-edgar","filing":"0000899243-22-039217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322039217/doc4.xml","form_type":"4"}},{"id":2078144,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2022-12-22T21:42:42.000Z","date":"2022-12-20","kind":"sale","acquired":false,"shares":600,"price":28.07,"value":16842.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.03 to $28.09. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.03 to $28.09. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-039217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322039217/doc4.xml","form_type":"4"}},{"id":2078143,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2022-12-22T21:42:42.000Z","date":"2022-12-20","kind":"exercise","acquired":true,"shares":600,"price":23.03,"value":13818.0,"ownership":{"direct":true},"balance_after":600,"source":{"system":"sec-edgar","filing":"0000899243-22-039217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322039217/doc4.xml","form_type":"4"}},{"id":2082606,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-20T00:22:53.000Z","date":"2022-12-16","kind":"exercise","acquired":false,"shares":1297,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":61647,"derivative":{"exercise_price":23.03,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":1297},"source":{"system":"sec-edgar","filing":"0000899243-22-039056","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322039056/doc4.xml","form_type":"4"}},{"id":2082605,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-20T00:22:53.000Z","date":"2022-12-15","kind":"exercise","acquired":false,"shares":300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":62944,"derivative":{"exercise_price":23.03,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":300},"source":{"system":"sec-edgar","filing":"0000899243-22-039056","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322039056/doc4.xml","form_type":"4"}},{"id":2082604,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2022-12-20T00:22:53.000Z","date":"2022-12-16","kind":"sale","acquired":false,"shares":1297,"price":28.44,"value":36886.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.72. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.72. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-039056","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322039056/doc4.xml","form_type":"4"}},{"id":2082603,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2022-12-20T00:22:53.000Z","date":"2022-12-16","kind":"exercise","acquired":true,"shares":1297,"price":23.03,"value":29869.91,"ownership":{"direct":true},"balance_after":1297,"source":{"system":"sec-edgar","filing":"0000899243-22-039056","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322039056/doc4.xml","form_type":"4"}},{"id":2082602,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2022-12-20T00:22:53.000Z","date":"2022-12-15","kind":"sale","acquired":false,"shares":300,"price":28.08,"value":8424.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-039056","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322039056/doc4.xml","form_type":"4"}},{"id":2082601,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2022-12-20T00:22:53.000Z","date":"2022-12-15","kind":"exercise","acquired":true,"shares":300,"price":23.03,"value":6909.0,"ownership":{"direct":true},"balance_after":300,"source":{"system":"sec-edgar","filing":"0000899243-22-039056","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322039056/doc4.xml","form_type":"4"}},{"id":2087010,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-15T01:56:50.000Z","date":"2022-12-14","kind":"exercise","acquired":false,"shares":15656,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":63244,"derivative":{"exercise_price":23.03,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":15656},"source":{"system":"sec-edgar","filing":"0000899243-22-038520","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322038520/doc4.xml","form_type":"4"}},{"id":2087009,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-15T01:56:50.000Z","date":"2022-12-12","kind":"exercise","acquired":false,"shares":600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":78900,"derivative":{"exercise_price":23.03,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":600},"source":{"system":"sec-edgar","filing":"0000899243-22-038520","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322038520/doc4.xml","form_type":"4"}},{"id":2087008,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2022-12-15T01:56:50.000Z","date":"2022-12-14","kind":"sale","acquired":false,"shares":15656,"price":28.12,"value":440246.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.33. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.33. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-038520","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322038520/doc4.xml","form_type":"4"}},{"id":2087007,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2022-12-15T01:56:50.000Z","date":"2022-12-14","kind":"exercise","acquired":true,"shares":15656,"price":23.03,"value":360557.68,"ownership":{"direct":true},"balance_after":15656,"source":{"system":"sec-edgar","filing":"0000899243-22-038520","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322038520/doc4.xml","form_type":"4"}},{"id":2087006,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2022-12-15T01:56:50.000Z","date":"2022-12-12","kind":"sale","acquired":false,"shares":600,"price":28.05,"value":16830.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.02 to $28.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.02 to $28.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-038520","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322038520/doc4.xml","form_type":"4"}},{"id":2087005,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2022-12-15T01:56:50.000Z","date":"2022-12-12","kind":"exercise","acquired":true,"shares":600,"price":23.03,"value":13818.0,"ownership":{"direct":true},"balance_after":600,"source":{"system":"sec-edgar","filing":"0000899243-22-038520","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322038520/doc4.xml","form_type":"4"}},{"id":2115270,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-16T23:45:46.000Z","date":"2022-11-15","kind":"exercise","acquired":false,"shares":8125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vested 25% on September 22, 2022 and the remainder vests in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":21875,"derivative":{"exercise_price":14,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":8125},"source":{"system":"sec-edgar","filing":"0000899243-22-036044","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322036044/doc4.xml","form_type":"4"}},{"id":2115269,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2022-11-16T23:45:46.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":8125,"price":22.05,"value":179156.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $21.04 to $22.845. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $21.04 to $22.845. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-036044","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322036044/doc4.xml","form_type":"4"}},{"id":2115268,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2022-11-16T23:45:46.000Z","date":"2022-11-15","kind":"exercise","acquired":true,"shares":8125,"price":14,"value":113750.0,"ownership":{"direct":true},"balance_after":8125,"source":{"system":"sec-edgar","filing":"0000899243-22-036044","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322036044/doc4.xml","form_type":"4"}},{"id":2415014,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":67804,"kind":"person","name":"Meisner Lara","position":1,"cik":"0001883986","reported_name":"Meisner Lara","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-03T23:12:07.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":90000,"derivative":{"exercise_price":18.51,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0000899243-22-004666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883986/000089924322004666/doc4.xml","form_type":"4"}}]}